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Abbriviations  
BMI  Body mass index 
CI   Confidence interval  
CIS  Clinically isolated syndrome 
CNS  Central nervous system 
DAG  Direct acyclic graph 
DSS  Disability Status Scale 
DMT  Disease modifying drugs  
EAE  Experimental autoimmune encephalomyelitis 
EBV   Epstein-Barr virus 
EBNA-1 Epstein-Barr virus nuclear antigen 1 
EDSS  Expanded Disability Status Scale  
EnvIMS  Environmental Risk Factors in Multiple Sclerosis  
EnvIMS-Q  Questionnaire for Environmental Risk Factors in Multiple Sclerosis  
IL  Interleukin 
IM   Infectious mononucleosis 
IU  International units  
MR  Mendelian randomization 
MS   Multiple sclerosis 
MRI  Magnetic resonance imaging 
NEDA No evidence of disease activity 
OR   Odds ratio 
PPMS  Primary progressive multiple sclerosis  
PTH  Parathyroid hormone 
RERI  Relative excess due to interaction 
RR  Rate ratio 
RRMS Relapsing-remitting multiple sclerosis 
SES  Socioeconomic status  
SNP  Single-nucleotide polymorphism 
SPMS  Secondary progressive multiple sclerosis 
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Treg  Regulatory T-cells 
UV  Ultraviolet 
UVB  Ultraviolet B 









Background: Multiple sclerosis (MS) is a chronic demyelinating disease of the 
central nervous system whose etiology is unknown. While several genetic factors and 
environmental exposures, including low vitamin D, smoking, infectious 
mononucleosis (IM) and obesity, have been consistently associated with increased 
MS risk, they are unlikely to fully explain the individual disease risk. Further, little is 
known about the underlying mechanisms by which they may affect disease risk.  
Objective: The main objectives of this study were to examine how exposure to 
selected environmental factors in specific age periods was associated with MS risk 
and to disclose whether the associations varied between different populations using 
the same methodology. In detail, we sought 1) to examine how frequency of outdoor 
activity, as a proxy for sun exposure and vitamin D levels, in specific age periods 
from birth to disease onset was associated with MS risk, 2) to examine to which 
degree prior exposure to known environmental risk factors could explain the 
association between level of education and MS risk and 3) to examine how the 
interplay between smoking and IM affected MS risk in our study populations.  
Methods: We used data from the large multi-national population-based case-control 
study Environmental Risk Factors in MS (EnvIMS), which included participants from 
Norway, Italy, Serbia, Sweden and Canada. For the two first articles, data from 
Norway and Italy was available, while for the third article data from Sweden was also 
available. In total, this included 1904 patients and 3694 controls. In the countries 
included in our analyses, patients were recruited from regional or national MS 
registries, while four times as many age and sex frequency-matched controls were 
randomly selected from population registries. All patients had been diagnosed 
according to the McDonald or the Poser criteria, and had clinical onset within 10 
years prior to data collection. All participants were older than 18 years at time of 
selection. Cases and controls in each country reported on prior exposure to selected 
environmental factors in specific age periods of life using an identical self-
administered questionnaire (EnvIMS-Q), which had been developed specifically for 
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our study. For the current analyses, information on outdoor activity, sunscreen use, 
hair color, smoking, IM, body size, cod liver oil supplementation, fatty fish intake 
and level of education was used. The controls were randomly assigned an index age 
based on the distribution of age of onset among the cases and exposure after disease 
onset or index age was not considered exposure. The association between disease and 
exposure was estimated as odds ratios (OR) with 95% confidence intervals (95% CI) 
using logistic regression. All analyses were adjusted for age and sex.  
Results: In the first article, we found a significant inverse association between 
frequency of outdoor activity and MS risk in Norway and Italy. The magnitude of the 
association was strongest between age 16 and 18 in Norway (OR 1.83, 95% CI: 1.30-
2.59), and between birth and age 5 years in Italy (OR 1.56, 95% CI: 1.16-2.10). We 
observed seasonal differences in the association in Norway, whereas we observed a 
significant association for outdoor activity during summer, but not in the winter. For 
Italy, the association was similar for summer and winter. In addition, we found a 
significant association between sunscreen use and MS risk during childhood in 
Norway after accounting for outdoor activity (OR 1.67, 95% CI: 1.06-2.63).  
In the second article, we found an inverse association between level of education and 
MS risk in Norway (OR highest vs lowest level: 0.53, 95% CI: 0.41-0.68). The 
association remained significant after adjusting for smoking, IM, outdoor activity, 
cod liver oil, fatty fish consumption and body size. Further, the association remained 
similar after we excluded patients with early onset of disease, defined as onset before 
age 28. 
In the third article, we found a statistical significant negative multiplicative 
interaction between smoking and IM in the risk of MS. Among those who reported 
IM, we observed no increased disease risk associated with smoking. Similarly, the 
effect estimates for the association between IM and MS risk were considerably lower 
among ever-smokers compared to never smokers. The interaction was similar in 
Norway, Italy, and Sweden. Lastly, we observed similar results on when estimating 
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the interaction on the additive scale, although they did not reach statistical 
significance. 
Conclusion: The findings of this study add to the evidence that vitamin D has a 
protective effect on MS risk, and indicate that adolescence is a sensitive period for 
exposure. Still, exposure earlier in life might also be of importance. Further, 
established risk factors cannot fully explain the association between level of 
education and MS risk in Norway, suggesting that currently unknown environmental 
exposures associated with lower level of education may be important for disease risk. 
Lastly, our findings indicate a competing antagonism between smoking and IM in the 
risk of MS, which suggests that the two risk factors operate on shared biological 
pathways.  
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1.1 Historical perspectives  
In 1822, Augustus d’Este (1794-1848), the grandson of King George III of England, 
started a detailed diary to describe various symptoms he had been experiencing.1 At 
age 28, he experienced blurred and gradually decreased vision to the extent that he 
could no longer read, which he thought was due to holding back his tears in a funeral. 
While his vision gradually improved, he experienced repeated episodes with vision 
loss followed by recovery over the next years. In 1827, he complained that heat was 
now intolerable to him, and in the following years the disease progressed and he 
developed numbness, increasing weakness in his legs and difficulty walking. His 
story is a characteristic picture of multiple sclerosis (MS), and is one of the first case 
reports of a disease that was not defined until 20 years after d’Este’s death.  
Jean-Martin Charcot (1825-1893), a French neurologist, gave a series of three 
lectures in 1868 where he defined a disease he referred to as “sclérose en plaque 
disséminées” or disseminated sclerosis,2 which later became known as MS. Based on 
clinical and pathological observations, he described a disease that closely resembles 
how we see the disease today.3 In the years that followed, more cases were described 
in the medical literature,4 and eventually efforts to find the cause of the disease 
began. 
1.2 Pathogenesis 
During the 19th century, Charcot and others noted that the disease that later become 
known as MS was characterized by a selective loss and disruption of the myelin 
sheet,3 a membrane structure surrounding the neuronal axon that is important both for 
signal transduction and protection of neurons. Areas of demyelination constitute focal 
lesions, and in these lesions axonal damage and degeneration may occur.5, 6 This can 
lead to disruption of neuronal signaling, which is manifested in the symptoms the 
patient is experiencing. Charcot and others noted early that axonal pathology 
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correlated with disability development,7 and it has later been widely agreed that 
axonal damage likely is a determinant of disease progression in MS.5 
Immune cells specifically targeting self-tissue are likely to initiate the disease 
processes in MS. During the differentiation of thymocytes in the thymus, most cells 
targeting self-tissue are eliminated, but some mature self-reactive T-cells may still be 
released into the peripheral circulation.8 These are normally kept in check by 
regulatory parts of the immune system, such as regulatory T (Treg)  cells, and remains 
inactivated.8 In MS, it has been proposed that a complex interaction between genetic 
predisposition and environmental triggers leads to an activation of peripheral self-
reactive T- and B-cells, which then may infiltrate the central nervous system (CNS) 
and lead to inflammation and eventually tissue damage.9 Triggers may induce 
activation of these cells directly by molecular mimicry, a cross-activation of self-
reactive immune cells due to structural resemblance between a foreign antigen and a 
self-antigen,10 or indirectly by inducing a pro-inflammatory environment that can 
lower the activation threshold of self-reactive cells.9 The precise mechanisms by 
which environmental exposures and genetic factor interact to eventually cause MS 
are still not known. 
1.3 Descriptive epidemiology 
There is a considerable regional variation in the distribution of MS across the world 
(Figure 1). In the 1950s, Kurland et al. used mortality statistics to estimate the 
prevalence of MS in selected regions in the US and Canada, and found a considerable 
higher prevalence in the north compared to the south,11 which was consistent with 
observations made by Davenport already in 1922.12 On the basis of these findings and 
similar findings made by others, it was suggested that an environmental exposure 
varying with latitude could be important for disease risk.13 In 1964, Kurtzke 
published one of the first reviews of prevalence studies, and divided the world into 
three frequency zones; a high prevalence zone consisting of northwest Europe, 
southern Canada and northern USA, a medium prevalence zone consisting of 
southern Europe, southern USA and Australia and a low prevalence zone including 
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the rest of the world.14 He noted that the prevalence seemed to be correlated with 
latitude, whereas the prevalence was very low in tropical areas close to the equator 
and increased with latitude with the highest prevalence in the most northern 
countries.15 A similar pattern is described in newer studies,16 although there are some 
exceptions to the suggested north-south gradient in prevalence.17 Furthermore, it has 
recently been reported that the gradient in the northern hemisphere appears to be 
attenuated.18  
 
Figure 1: Worldwide prevalence of multiple sclerosis 
The figure illustrates the distribution of MS across the world with prevalence 
reported per 100 000 population. Reprinted by permission from Elsevier: The Lancet 
Neurology 3: 710,19 © Copyright 2004 
MS was initially thought to be equally prevalent in men and women, or even 
dominated by men.20 Early observations in the end of the 19th and beginning of the 
20th century were likely affected by ascertainment bias, as some women with MS 
were misdiagnosed with hysteria, while men with MS tended to be more accurately 
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diagnosed as they dominated the work force.21 More recent studies consistently report 
a higher prevalence in women than in men, which may be due to better ascertainment, 
but also likely to reflect a real increasing incidence in women compared to men over 
time.22 The incidence of the disease is highest in young adults, and age of onset peaks 
between 25 and 35 years.23 
1.4 Disease characteristics 
There are two main disease phenotypes in MS, relapsing and progressive disease.24 
Relapsing disease is characterized by relapses followed by partial or complete 
recovery, and is referred to as relapsing-remitting MS (RRMS).24 A relapse is defined 
as symptoms or signs typical of an acute inflammatory demyelinating event in the 
CNS with duration of at least 24 hours in the absence of fever or infection.25 RRMS 
is the most common course at disease onset, and accounts for approximately 85% of 
the patients.26 The first relapse is referred to as clinically isolated syndrome (CIS), 
which do not fulfill the criteria of MS diagnosis, but is sometimes included in the 
spectrum of MS phenotypes.24 Progressive disease is characterized by a gradual 
accumulation of disability over time without clear periods of recovery, and is referred 
to as primary progressive MS (PPMS) when it is present from disease onset and 
secondary progressive MS (SPMS) if it occurs after an initial course of RRMS.24 
Common initial symptoms are sensory, motor or visual disturbances consistent with 
demyelinating lesions in the brain, spinal cord, brainstem or optic nerve.26 It was 
early suggested that a definitive diagnoses of MS should be based on dissemination 
of lesions in time and space,27 which is still the case today. According to the newest 
diagnostic criteria, the 2010 revision of the McDonald criteria, patients with evidence 
of dissemination of time and space on a single magnetic resonance imaging (MRI) 
scan can be diagnosed with definitive MS.25 In the study that this thesis is based on, 
cases with a definite or probable diagnosis according to McDonald (2005 revision)28 
or the Poser29 criteria were included. 
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Further progression of the disease appears to be fairly homogenous on a population 
level, although there is considerable variation between affected individuals.30 Most 
patients with untreated RRMS will eventually develop SPMS,31, 32 which similarly to 
PPMS is associated with development of irreversible disability,33 as illustrated in 
Figure 2. In prospective cohort studies of untreated patients, the median time to a 
score of 6 on the Disability Status Scale (DSS), corresponding to inability to walk 
unsupported,34 has been reported to range from 14 to 20 years after disease onset,26, 35, 
36 although longer time intervals has been reported.37 In patients on disease modifying 
treatment (DMT), the risk of reaching 6 on the Expanded Disability Status Scale 
(EDSS) appears to be lower compared to untreated patients,38 although no effect of 
treatment on progression has also been reported.39, 40 The overall survival among 
patients appears to have improved over time, but the life expectancy is still 
considerable lower than age-matched populations without MS.41, 42  
 
Figure 2: The heterogeneity of multiple sclerosis. 
The figure illustrates the course of disease in patients with RRMS, SPMS and PPMS 
according to average age and disability accumulation. Reprinted by permission from 
Macmillan Publishers Ltd: Nature Reviews Immunology 15: 546,9 © Copyright 2015 
 20 
1.5 Environmental risk factors 
1.5.1 Evidence for environmental risk factors 
While there is strong evidence that genetic predisposition contributes to the risk of 
MS,43, 44 it cannot fully explain individual disease risk. The concordance rate in 
monozygotic twins has been reported to be approximately 25%, with a sharp decrease 
in risk with increased genetic distance to the individual affected by the disease 
(Figure 3),45, 46 illustrating the importance of genetic susceptibility, but also 
suggesting that environmental risk factors play an important role in the etiology of 
MS. However, as illustrated by Figure 3, the concordance rate for MS in monozygotic 
twins is lower than what has been reported for rickets and polio, which are both 
caused by environmental factors.47 The change in risk among individuals who 
migrate to areas with different MS prevalence, the change in incidence and sex ratio 
over time and the consistent associations between specific environmental risk factors 
and disease risk further add to the evidence that environmental exposures contributes 
to individual disease risk.48 
 
Figure 3: Twin and sibling concordance in rickets, polio and multiple sclerosis. 
The figure illustrates how disease risk decreases with increasing genetic distance 
from the affected individual. Reprinted by permission from Elsevier: The Lancet 
Neurology 7(3): 271,47 © Copyright 2004 
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Migration studies represent a natural experiment where the population is changing 
their environment over a short period of time, and has been useful to understand 
aspects of MS.49 In 1970, Kurtzke et al. noted that the prevalence of MS among 
migrants that earlier had moved from North Europe to South Africa varied by age at 
migration.50 Among those who moved while they were under age 15, prevalence was 
about the same as that of the white native-born population, while prevalence among 
those aged more than 15 at time of migration was similar to that in their homeland. 
This suggests that environmental exposures varying in the two regions are important 
for disease risk, and that the age period before age 15 likely is a sensitive period. 
Similar findings have been documented for migrants moving from low- to high-risk 
areas51, 52 and for within-country migration.53 
Several studies have reported an increased incidence of MS over time, and the 
increase appears to be more pronounced in women compared to men.22 In a 
systematic review of prevalence and incidence studies from 1950 to 2010, Koch-
Henriksen et al. found a significant increase in incidence with time (Figure 4),22 
suggesting that the findings are not due to improved survival of MS-patients. 
Similarly, most studies with repeated surveys over time in the same population report 
increased incidence and prevalence.22 Orton et al. calculated sex ratio in MS-patients 
by year in a population-based cohort over 50 years, and observed that the ratio has 
increased from 1.9:1 in 1931-1935 to 3.2:1 in 1976-1980,54 which is consistent with 
studies in Denmark and Norway with similar follow-up time.22, 55 While better 
ascertainment and more sensitive diagnostic criteria may have contributed to a higher 
number patients being accurately diagnosed with MS, and thus higher reported 
incidence rates of the disease in newer studies, it is unlikely that this can fully explain 
the observed changes.22 A clear increase in incidence and a change in sex ratio over 
time cannot be explained by genetic predisposition alone, as the time period is too 
short for major changes in the genetic material to occur.  
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Figure 4: Prevalence and incidence rates from 1950 – 2010. 
The figure illustrates the increase in prevalence (A) and incidence rates (B) in 
Western Europe and North America during the period 1950 – 2010. Reprinted by 
permission from Elsevier: The Lancet Neurology 9(5): 525,22 © Copyright 2010 
Lastly, several environmental exposures have consistently been associated an altered 
MS risk, including Epstein-Barr virus infection, vitamin D, smoking and obesity,48 
arguing for a role of these exposures in the etiology of the disease.  
1.5.2 Epstein-Barr virus and infectious mononucleosis 
Already in the 19th century, it was proposed by Pierre Marie, a student of Charcot, 
that an infection could be the cause of MS.3 In 1975, Kurtzke et al. described MS as 
an epidemic disease in the Faroe Island, as the authors could not document a single 
patient with onset prior to 1943 among individuals who had not spent longer periods 
of time abroad, but observed a sharp increase in incidence after this year.56 The 
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authors argued that the most likely explanation for these observations was a persistent 
infection introduced by British troops that occupied the island from 1940-1945, and 
referred to it as primary multiple sclerosis affection. Although an agent for such an 
infection has not been identified, and the interpretation of the findings have been 
questioned by other investigators,57 the observations could argue for a role of an 
infectious disease in the etiology of MS. 
In 1963, Poskanzer et al. noted that there were similarities between MS and 
poliomyelitis, as they had a similar distribution with latitude.58 It had previously been 
suggested that the distribution of poliomyelitis was due to differences in sanitation, 
whereas poor sanitation in early life was associated with higher rate of infection with 
the virus, but lower rates of paralytic disease. On the other hand, better sanitation in 
childhood was associated with infection later in life and increased risk of paralytic 
disease. As sanitation varied with latitude, this could explain the geographical 
distribution of the disease. Similarly, if MS was due to an infection and the risk varies 
with age at infection, the distribution of the disease could be explained by sanitary 
conditions. A range of different bacterial and viral agents have been proposed to 
affect MS risk, but EBV is the only agent that consistently has been associated with 
in increased MS risk.59 EBV has similarities with the infectious agent proposed by 
Poskanzer et al., as the age at primary infection varies between developing and 
developed countries,60 and thus likely sanitary conditions, and an infection later in 
life is associated with a higher risk of symptomatic disease,60 referred to as infectious 
mononucleosis (IM), which consistently has been associated with an increased MS 
risk.59 Furthermore, MS risk appears to be very low among EBV negative 
individuals,61 suggesting that higher sanitary condition is not a common cause for 
both IM and MS, but that EBV actually contributes to MS risk. 
The strongest evidence for EBV in MS risk comes from prospective studies with 
serum samples prior to MS onset. In a nested case-control study among military 
personnel in the USA, Munger et al. found that serum titers prior to MS onset of a 
specific antibody, EBV nuclear antigen (EBNA-1), was significantly associated with 
subsequent MS risk, with the highest levels being associated with a 36-fold increased 
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risk.62 An independent Swedish study also found associations between EBNA-1 and 
MS risk,63 and together they could indicate that an altered immune response to EBV 
affects MS risk. Further, Levin et al. identified EBV negative individuals who later 
developed MS in the cohort of military personnel, and found that all of them 
contracted EBV before developing the MS (Figure 5), compared to 36% among those 
who did not develop MS.64 This could suggest that the findings are not due to reverse 
causality, and that EBV may be necessary, but not sufficient for MS to develop. Still, 
the number of individuals that initially were EBV negative and later developed MS 
was low.  
 
Figure 5: Time of EBV seroconversion and MS onset. 
The figure illustrates the follow-up of 10 EBV negative individuals that later 
developed multiple sclerosis. The horizontal lines represent serum samples in 
individuals; Yellow bar is months as EBV negative, the green bar is months as EBV 
positive and the blue circle is MS onset. Reprinted by permission from Nature 
Publishing Group: Nature Reviews Neurology 8(12): 602,65 © Copyright 2012 
 25 
It is still unclear by which mechanisms EBV affects MS risk. It could involve cross-
reactivity (i.e. molecular mimicry) between EBV-specific antigens and myelin-
specific epitope, as MS patients appears to have increased levels of EBNA-1 specific 
CD4+ T-cells that also has a broader specificity for epitope recognition compared to 
EBV positive controls,66 and these T-cells recognize myelin antigens more often than 
other antigens.67  
1.5.3 Vitamin D and sun exposure 
In 1960, Acheson et al. were the first to suggest that sun exposure could be protective 
for MS, after finding a significant correlation between hours of solar radiation and the 
geographical distribution of the disease.68 Higher levels of sun exposure or more 
frequent outdoor activity have later consistently been associated with a lower MS risk 
in several case-control studies from different parts of the world, including Australia,69 
Norway70 and Sweden.71 It has been proposed that the association could be due to 
immunosuppressive effects due to suppression of melatonin72 or through induction of 
Treg cells and regulation of the cytokines interleukin (IL) 10 and IL-17.73 The 
association is now mainly interpreted to be mediated by vitamin D, as sun exposure is 
an important source of the vitamin,74 but an association between actinic damage, a 
marker of cumulative sun exposure, and lower MS risk independent of vitamin D 
levels has also been reported.73 
Vitamin D is a fat-soluble vitamin that humans mainly get from exposure to sun, but 
also in smaller amounts through diet and dietary supplements,74 as illustrated by 
Figure 6. The vitamin D synthesis by sun exposure is initiated when 7-
dehydrocholesterol is converted to previtamin D3 by ultraviolet B (UVB) rays 
penetrating the skin.74 The amount of UVB radiation reaching the earth’s surface 
varies markedly with season and latitude, as photons at low solar zenith angle have to 
travel for longer distances through the ozone level, which increases the absorption.75 
Therefore, there are marked seasonal and latitudinal variations in vitamin D synthesis 
by sun exposure. Previtamin D3 is converted to Vitamin D3 and then to 25-
hydroxyvitamin D,74 which is often is used as a marker vitamin D status due to its 
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long half-life and because the conversion of vitamin D3 to 25-hydroxyvitamin D in 
the liver is not tightly regulated but depends more on the concentration of vitamin 
D3.76 Eventually, 25-hydroxyvitamin D can be converted to 1,25-dihydroxyvitamin 
D, which is the active form of vitamin D, and this conversion is tightly regulated by 
serum parathyoroid hormone (PTH), calcium and phosphorus levels.74 For this reason 
and because of its short half-life, 1,25-hydroxyvitamin D is not a useful marker of 
vitamin D status. 
 
Figure 6: Metabolism of vitamin D. 
The figure illustrates the metabolism of vitamin D from sun exposure and diet. 
Vitamin D is obtained either directly through diet, or after a conversion of 7-
dehydrocholesterol to pre-vitamin D by sun exposure in the skin and a further 
conversion to vitamin D in the body. Vitamin D is converted to 25-hydroxyvitamin D 
in the liver and further to its active form 1,25-dihydroxyvitamin D in the kidneys and 
other organs. Reprinted by permission from Elsevier: The Lancet Neurology 9(6): 
600,77 © Copyright 2010. 
Goldberg first proposed the vitamin D hypothesis for MS in 1974.78 However, most 
of the evidence for a role of the vitamin in MS etiology comes from studies 
conducted the last 15 years. Two nested case-control studies assessed the association 
between preclinical serum-levels of 25-hydroxyvitamin D and MS risk, and found an 
inverse association suggesting a protective role of the vitamin.79, 80 However, a 
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challenge with these findings is to separate the effect of vitamin D and sun exposure, 
as the two are highly correlated.73 In a large prospective study of female U.S. nurses, 
Munger et al. found a significant inverse association between supplemental vitamin D 
intake and MS risk, whereas a daily intake of more than 400IU/D was associated with 
a 40% lower risk,81 suggesting that vitamin D itself is protective for MS. This is 
consistent with some,70, 82, 83 but not all,69 case-control studies, where intake of 
supplements or food rich in vitamin D have been associated with a lower MS risk. 
Lastly, two studies using Mendelian randomization (MR) found an inverse 
association between single-nucleotide polymorphisms (SNPs) predicting vitamin D 
levels and MS risk.84, 85 MR studies use genetic information as an instrumental 
variable, and can therefore avoid some of the bias associated with observational 
studies,86 as illustrated in Figure 7. While there are methodological challenges with 
MR studies,87 the results from these studies argue for a causal role of vitamin D in 
MS etiology and against that the association between vitamin D and MS risk is due to 
confounding by sun exposure. 
 
Figure 7: Instrumental variable and Mendelian randomization. 
The figure is a directed acyclic graph (DAG) of an instrumental variable Z, the 
exposure X, the outcome Y and measured or unmeasured common causes (i.e. 
confounders) U. Z is an instrumental variable as it has a causal effect on X, only 
affects Y through X and does not share a common cause with Y.88 In MR studies, 
genetic information may be interpreted as an instrumental variable, and they are thus 
not depending on measuring all confounders to estimate the effect of the exposure on 
the outcome, given that the genetic information meets all the assumptions of an 
instrumental variable. Reprinted by permission from Wolters Kluwer Health, Inc.: 
Epidemiology 17(4): 361,88 © Copyright 2006. 
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Vitamin D has immunomodulatory properties that may be relevant for MS. 1,25-
dihydroxyvitamin D appears to be effective in preventing and attenuating the disease 
progression in experimental autoimmune encephalomyelitis (EAE),89 a commonly 
used animal model of MS, likely through pathways involving IL-10, Treg and vitamin 
D receptors (VDR) in T cells.90-92 The role of 25-hydroxyvitamin D is less clear, as it 
only appears to be effective in female mice.93 Serum level of 25-hydroxyvitamin D 
has been correlated with frequency and function of Treg cells in humans.94, 95 This 
suggests that vitamin D can modulate Treg activity, which have been reported to be 
impaired in MS.96 Furthermore, both 25-hydroxyvitamin D and 1,25-
dihydroxyvitamin D have been associated with a reduction in the proportion of 
conventional Th17-cells,97, 98 which appears to be increased in MS patients and are 
likely to be relevant for MS pathogenesis.99 It has also been hypothesized that 25-
hydroxyvitamin D could be directly involved in thymic negative selection, as the 
number of signal joint TCR excision circles, a marker of thymic output, has been 
reported to be inversely correlated with 25-hydroxyvitamin D levels.100 In prospective 
studies of MS patients, higher levels of 25-hydroxyvitamin D have been associated 
with reduced disease activity and slower progression.101, 102 The results from 
intervention studies have been less clear, which may be due to relatively small sample 
size and short follow-up, but some studies have reported significantly lower number 
of new lesions in the vitamin D group compared to placebo.103, 104  
1.5.4 Tobacco smoking 
The first studies on smoking and MS risk were conducted in the 1960s, after it had 
been reported that smoking could aggravate symptoms in MS patients.105, 106 
Antonovsky et al. first reported an association between smoking and MS risk in 1965, 
after finding a significant higher proportion of smokers before age of onset among 
MS patients compared to controls in an Israeli population-based case-control study.13 
The findings were inconsistent with a study published the year after, where no 
association between current smoking and MS risk was found when using control data 
from a national survey of smoking in Great Britain.107 Still, as the MS patients in this 
study may have changed smoking habits after disease onset, the use of current 
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smoking as exposure makes the results from this study are less informative.108 In the 
1990s, two prospective studies on oral contraceptives and MS risk, reported findings 
indicating a possible association between smoking and MS risk, although the 
associations were not statistical significant.109, 110  
In the years that followed, there was an increased interest in the association and 
several new studies were conducted. Ghadirian et al. found a significant higher risk 
among ever-smokers compared to never-smokers in a Canadian case-control study, 
and reported a clear dose-response relationship between the number of cigarettes 
smoked per day and MS risk.111 However, as information on prior smoking habits 
was collected after disease onset, the findings could have been prone to differential 
misclassification by disease status, or recall bias. Hernan et al. prospectively 
examined the association in two cohort studies of female nurses in the US in 2001, 
and found a significant higher risk in current smokers compared to never-smokers 
and a significant dose-response relationship between pack-years of smoking and MS 
risk.108 Riise et al. reported similar findings in 2003 in a study that included a large 
general population in Norway.112 Consistent findings have later been reported from 
several different countries, including England,113 Serbia,114 Sweden,115 Iran,116 and 
Australia.117 Further, elevated levels of cotinine, a marker of current smoking, 
measured before MS onset has also been associated with a higher MS risk.118 
Smoking is now considered to be one of the risk factors most consistently associated 
with the development of MS in the general population.48, 59  
The susceptibility for MS associated with smoking seems to vary with smoking 
habits. In a recent meta-analysis, there was a significant difference between current 
smoking and past smoking, whereas current smoking was associated with an 83% 
increased risk and past smoking was associated with a 58% increased risk, compared 
to non-smokers.119 Only a few studies have examined the association between passive 
smoking and MS risk,120-122 and in the recent meta-analysis it was significantly 
associated with a 24% increased risk compared to individuals not exposed to 
smoking.119 Further, Hedström et al. reported no significant association between 
smoking and MS risk 10 years after smoking cessation, regardless of the cumulative 
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dose of prior smoking.120 Lastly, smoking may have different effects in men and 
women, as there was a significant effect modification by sex in the pooled analysis in 
the meta-analysis, where smoking in men was associated with a higher risk compared 
to in women.119 
It is unknown by which mechanisms smoking affect MS risk, but several pathways 
have been suggested. In a Swedish study, tobacco smoking was associated with an 
increased risk, while use of the oral tobacco snuff was associated with a lower risk,115 
suggesting that mode of delivery is of importance and that the effect is not due to 
systemic effects of nicotine. This is consistent with an EAE study, where nicotine 
ameliorated symptoms, while non-nicotine components induced demyelination and 
microglial activation, leading to a worsening of the symptoms.123 Interestingly, 
bronchus-associated lymphoid tissue in the lungs appears to be central in the 
activation of self-reactive T-cells,124 which is also consistent with findings from the 
Swedish study. Lastly, smoking may reduce indoleamine 2,3-dioxygenase activity 
and increase the activity of the renin–angiotensin system, which both were associated 
with reduced numbers of Treg in a study on MS patients.125  
1.5.5 Obesity 
Ghadirian et al. first evaluated the association between weight and MS risk in 1998, 
and observed that higher BMI was associated with a significant lower risk.126 
However, as the participants were asked to report weight at time of diagnosis, the 
findings might have been prone to reverse causation, as MS patients tend to weight 
less than controls after onset.127, 128 Munger et al. prospectively examined the 
association in two cohort studies of female nurses, and observed a two-fold increased 
risk among participants reporting to be obese (body mass index [BMI] equal or above 
30)129 compared to those reporting BMI between 18.5 and 21 at age 18.128 Similar 
findings were observed in a large Danish registry-based study that included children 
born between 1930 and 1983, where higher BMI at age 7 to 13 was significantly 
associated with increased MS risk.130 The association was only significant in girls, 
which the authors argued to some extent could be due to power issues rather than 
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indicating an effect modification by sex. Three case-control studies with participants 
from Norway, Sweden, Italy and the US have reported findings consistent with the 
prospective studies.131-133 Further, a recent MR study found a significant association 
between SNPs predicting BMI and MS risk,134 which may indicate a more causal role 
of BMI on disease risk.  
Several mechanisms have been proposed to explain the association between being 
overweight and MS risk. It could to some extent be mediated by vitamin D, as serum 
25-hydroxyvitamin D was inversely associated with BMI in a systematic review of 
observational studies,135 and SNPs predicting BMI were significantly associated with 
lower 25-hydroxivitamin D levels in a MR study.136 Obesity is associated increased 
uptake and storage of 25-hydroxyvitamin D by adipose tissue,137 leading to lower 
bioavailability of the vitamin. However, the association could also be affected by 
increased catabolism of 25-hydroxyviatmin D due to the presence of 25-
hydroxyvitamin D-1α-hydroxylase in adipose tissue and by behavioral differences, 
which may lead to less sun exposure.138, 139 Obesity is also associated with chronic 
inflammation that can be relevant for MS susceptibility,140 and adipose tissue can 
modulate immune responses by secreting adipokines, which have been associated 
with lower number of Treg.141 
1.6 Timing of exposure to risk factors for MS 
Converging evidence from studies on established risk factors suggest that 
adolescence and young adulthood are sensitive exposure periods for later MS risk.79, 
118, 128, 142 However, most studies rely on exposure assessment at one or few time 
points, and thus only have exposure information in limited age periods for each 
participant. As those reporting exposure in one age period (e.g. tobacco smoking 
initiated as a teenager) may be different than those reporting exposure in a different 
age period (e.g. tobacco smoking initiated as adult), it can be difficult to make 
inferences on sensitive periods from these studies. While some studies have assessed 
exposure in several age periods,69, 70 studies assessing exposure from birth to disease 
onset using the same methodology are needed.  
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1.7 Socioeconomic status and MS 
MS is one of few diseases where high socioeconomic status (SES) has been 
associated with increased disease risk. Miller et al. published one of the first studies 
on SES and MS risk in 1960, after observing that the disease seemed to be more 
common in higher-income groups.143 The authors compared the occupation in 271 
male and 388 female MS patients with the general male population in 
Northumberland and Durham in England, and found that a higher proportion of MS 
patients were in the Registrar General social class I, corresponding to professional 
occupations, compared to the general population, while a lower proportion of the 
patients were in the social class IV, corresponding to unskilled occupations, 
compared to the general population. It was noted that the findings could give clues on 
the etiology of MS if they were replicated in other studies, as findings on SES and the 
risk of poliomyelitis and coronary thrombosis had given clues about risk factors. 
Russel published similar findings in 1971, where he observed a higher proportion of 
MS patients in the highest social classes, compared to the general population.144 
Furthermore, in a large nested case-control study of US army veterans, Kurtzke and 
Page found a higher MS risk among those with more than 9 years of education.145  
Several more recent studies do not show the same association between SES and MS 
risk, and some have even reported an inverse association. Ghadarian et al. found a 
significant lower risk among participants with more than 18 years of education in a 
Canadian case-control study,111 and Riise et al. found a significant lower risk among 
participants with a graduate degree compared to those with only elementary school in 
a Norwegian registry-based study with close to 400,000 participants.146 Briggs et al. 
found significant associations between several measures of low SES and higher MS 
risk, including education, social mobility and home ownership, which remained 
similar after adjusting for several risk factors for MS.147 The conflicting results could 
reflect a change in the distribution of environmental exposures relevant to MS over 
time or geographical differences in access to education, but could also reflect 
methodological limitations in early studies. 
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SES could be a marker of exposures relevant for MS etiology. It has been proposed 
that the hygiene hypothesis to some extent can explain associations between high 
SES and higher MS risk,148 as delayed exposure to infections early in life may affect 
the development of the immune system and make the individual more vulnerable 
altered immune response later in life. It is possible that these associations to some 
extent could be mediated by IM, as the risk depends on age at primary EBV 
infection,60 which is likely to depend on sanitation and thus SES. On the other hand, 
smoking and being overweight are both associated with lower SES,149, 150 and could 
mediate the association between lower SES and higher MS risk. If SES is associated 
with MS risk independently of known risk factors, it could give clues on currently 
unknown risk factors that may be important for the disease.  
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2. Study rationale and objective 
2.1 Rationale 
While several environmental exposures have consistently been associated with MS 
risk, the mechanisms by which they affect disease risk remain little understood. More 
information on these risk factors, when in life they are most important and how they 
interact can give clues on underlying mechanisms. 
Cohort studies are usually preferred over other study designs in epidemiology, as they 
are less prone to bias. However, due to the age distribution and the relatively low 
incidence of MS, it is challenging to conduct a cohort study with sufficient power to 
examine relevant exposures in detail. As a case-control study observes a population 
more efficiently compared to a cohort study, it is useful in settings where the outcome 
is rare.151 For this reason, we conducted a large multinational case-control study to 
examine environmental exposures suggested to be important in cohort studies in more 
detail.  
2.2 Objectives 
The objectives of this study were to: 
1) Examine how frequency of outdoor activity, as a proxy for sun exposure and 
vitamin D levels, in specific age period from birth to disease onset was associated 
with MS risk. 
2) Examine to which degree prior exposure to the known environmental risk factors 
smoking, IM, indicators of vitamin D and body size could explain the association 
between level of education and MS risk. 




3.1 Source of data: The EnvIMS Study 
3.1.1 Study design 
The Environmental Risk Factors in MS Study (EnvIMS study) is a large case-control 
study designed to assess the association between self-reported exposure to infections 
(including IM), vitamin D related factors (including sun exposure, dietary intake) and 
lifestyle factors (including smoking and body size) and MS risk, and to disclose 
possible variations in risk in different populations using common methodology. 
Investigators from Norway, Italy, Sweden, Serbia and Canada designed and 
conducted the study. A detailed overview of the study has previously been 
published.152 
3.1.2 Study area 
The coordination and participant recruitment was conducted in each country 
separately. As only data from Norway, Italy and Sweden were available for this 
study, the description will be limited to these countries. 
Norway:  
Norway is a country situated between 58 and 71 degrees northern latitude. It has an 
estimated MS prevalence of 203 per 100,000, ranging from 142 to 275 per 100,000 in 
different counties.55 Participants in the Norwegian part of EnvIMS were recruited 
throughout the country, and the recruitment and data collection were conducted from 
2009 to 2011. Researchers from the University of Bergen coordinated the study.  
Italy and Republic of San Marino:  
In Italy, participants were recruited from Sardinia and Ferrara. Sardinia is an island 
situated between 38 and 41 degrees northern latitude and has a MS prevalence that 
has been reported to exceed 150 per 100,000.153 Ferrara is a province situated in 
northern Italy at 44 degrees northern latitude, and has a MS prevalence that has been 
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reported to exceed 120 per 100,000.154 The Republic of San Marino a small country 
surrounded by Italy, and is situated at 43 degrees northern latitude. It has been 
reported to have a MS prevalence that exceed 160 per 100,000.155 All areas were 
combined in one dataset in the analysis. The recruitment and data collection were 
conducted from 2009 to 2010. Researchers from the University of Sassari coordinated 
the study.  
Sweden: 
Sweden is a country situated between 55 and 69 degrees northern latitude. It has been 
reported to have a MS prevalence of 189 per 100,000, ranging from 168 to 227 per 
100,000 in different counties.156 Participants in the Swedish part of EnvIMS were 
recruited from the counties of Östergötland and Värmland, and the recruitment and 
data collection were conducted from 2009 to 2014. Researchers from the University 
of Linköping coordinated the study. 
3.1.3 Selection of cases 
All cases included in the study were aged 18 years or older at time of selection, were 
diagnosed according to the McDonald28 or the Poser29 criteria and had clinical onset 
within 10 years prior to data collection. The cases were identified using population-
based registries in the different countries. 
Norway: 
The Norwegian MS patients were recruited from the Norwegian MS registry and 
Biobank.157 Among the 1368 eligible cases invited to the study, 953 (69.7%) chose to 
participate.  
Italy: 
The Italian MS patients were recruited from established regional patient registries in 
Sardinia, Ferrara and Republic of San Marino. Among the 1692 eligible cases invited 
to the study, 707 (41.8%) chose to participate. 
Sweden: 
The Swedish MS patients living in the counties of Östergötland and Värmland were 
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recruited from the Swedish MS registry.158 Among the 381 eligible cases invited to 
the study, 259 (68.0%) chose to participate. 14 of these had missing on age of onset 
and one had disease duration of more than 10 years. The final number of cases 
included in the analyses were therefore 244.  
3.1.4 Selection of controls 
Controls were randomly selected from population-based registries in each region 
under study. Four controls were selected per case, and they were frequency-matched 
on age (within 5 years) and sex. The lists of controls were crosschecked with the 
registries used for selection of cases to ensure that no MS patients were selected as 
controls. 
Norway: 
Statistics Norway159 randomly selected the Norwegian controls from the Norwegian 
National Registry,160 which contains information on everyone who has or is resident 
in Norway. Among the 4728 individuals invited to take part in the study, 1717 
(36.3%) responded and were included. 
Italy: 
The Italian controls were randomly selected from population-based registries in 
Sardinia, Ferrara and Republic of San Marino. Among the 6414 individuals invited to 
take part in the study, 1333 (20.8%) responded and were included. 
Sweden: 
Statistics Sweden161 randomly selected the Swedish controls living in the counties of 
Östergötland and Värmland from the Swedish Population Register,162 which contains 
information on everyone who has or is resident in Sweden. Among the 1734 
individuals invited to take part in the study, 645 (37.2%) responded and were 
included. One of these controls missed study age. The final number of controls 
included in the analyses were therefore 644. 
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3.1.5 Assessment of exposure with EnvIMS-Q 
A detailed description of the questionnaire used in EnvIMS, the EnvIMS-Q, has 
previously been published.163 It was designed to be a short self-administered 
questionnaire that could capture detailed information on exposures likely to be 
relevant in MS etiology. It was first developed in English, and then translated to 
Italian, Norwegian, Swedish, Serbian and French, and has been tested for feasibility, 
acceptability and reliability in pilot studies in each of the participating countries. The 
questionnaire contains some core questions that are identical in each country, to allow 
for comparison of associations in different populations, and some country-specific 
questions, to allow for examination of specific hypothesis only relevant for some of 
the countries. The questionnaire was identical for cases and controls. 
For the articles in this thesis, information on sun exposure, IM, smoking, body size, 
cod liver oil, fish intake and demographic variables were used. From the section on 
sun exposure, we included questions on frequency of outdoor activity during summer 
and winter (reported as ‘not that often’, ‘reasonably often’, ‘quite often’ and ‘virtually 
all the time), frequency of sun cream use (Norway and Sweden; reported as ‘Not so 
often’, ‘Sometimes’, ‘Quite often’ or ‘Almost always’), and frequency of sun cream 
use and protective clothing (Italy; reported as ‘Not so often’, ‘Sometimes’, ‘Quite 
often’ or ‘Almost always’). In Norway and Sweden, the exposure was reported in 
age-periods adapted to the educational system (0–6, 7–12, 13–15, 16–18, 19–24, 25–
30 and last 3 years), while five-year intervals were used in Italy (0-5, 6-10, 11-15, 16-
20, 21-25, 26-20 and last 3 years). Further, we included information on skin colour 
(range from 1 to 10 with skin tones from light to dark), reaction to sun without sun 
cream (reported as “I always get sunburned and never tan”, “I usually get sunburned 
and tan less than others”, I sometimes get sunburned and tan like others” and “I 
seldom get sunburned and easily tan”), natural hair colour (reported as “dark”, “dark 
brown”, “brown”, “blonde/yellow” and “red”) and eye colour (reported as “black”, 
“brown”, “grey/green” and “blue”). From the section on IM, we included questions 
on whether the responder had experienced IM (reported as “yes”, “no” and “I do not 
remember) and when they contracted the disease (reported using the same age periods 
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as for sun exposure). From the section of smoking, we used questions on whether the 
responder ever had been a daily smoker (reported as “yes” and “no”) and age at 
smoking onset (the responder was asked to fill in age in years). From the section on 
body size, we included the question on body shape (reported using body silhouettes 
on Stunkard´s figure rating scale164) at age 5, 10, 15, 20, 25, 30 and current age. From 
the section on diet, we included the questions on intake of fish from the Norwegian 
questionnaire (included questions on intake of the specific fish species herring, 
mackerel, halibut, flounder, salmon and trout and was reported as “never/seldom,” “1 
time/ month,” “2–3 times/month,” “1 time/week,” “2 times/ week” and “3 and more 
times/week” for each species) and use of cod liver oil from the Norwegian 
questionnaire (reported as “never/seldom,” “1–3 times/month,” “1 time/week,” “2–3 
times/week,” “4–6 times/week” and “7+ times/ week” in the age period 13 to 19). 
From the section on demographic information, we used information on the 
responder’s education in the Norwegian questionnaire (reported as “7 years or less” 
(elementary school), “8– 10 years” (middle school), “11–13 years” (high school), “14 
years or more” (college/university) and “I do not know”). 
3.1.6 Ethical approval and patient consent 
Regional ethical committees in each participating country approved the EnvIMS 
study. Return of the questionnaire was considered as evidence of consent. 
3.2 Statistical analysis 
3.2.1 Main analyses 
Exposure after disease onset was not considered relevant exposure among the cases. 
To make sure cases and controls had similar exposure opportunities, we randomly 
assigned an index age to all controls based on the distribution of age at MS onset 
among the cases, and did not consider exposure after index age as relevant exposure. 
The associations between the exposure of interest in the different articles and MS risk 
were estimated as odds ratios (OR) with 95% confidence intervals using logistic 
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regression. The exposures were included as categorical variables for the main 
analyses, and included as a continuous variable to test for trend. All analyses were 
adjusted for sex and age.  
For some variables, we combined categories to ensure that there were enough 
participants in each category. In the second article, we combined the two lowest 
levels of education (“7 years or less” and “8-10 years”), and the new variable had 
thus three levels corresponding to compulsory education, high school and higher 
education (College/University). Furthermore, we generated a new variable to account 
for intake of any fatty fish and categorized this variable as “never”, “1-2 
times/month”, “3-4 times/month”, “5-6 times/month” and “7 or more times/month”, 
corresponding to the categorization in a different article on fish intake and MS risk in 
EnvIMS.83 
For the two first articles, the analyses were done in IBM SPSS Statistics, while in the 
last article STATA was used.  
3.2.2 Interaction analysis 
In the third article, we focused on the interaction between IM and smoking. In line 
with recommendations in a recent guide on interaction analyses,165 we estimated this 
both on the additive scale and on the multiplicative scale. For the additive scale, we 
estimated the interaction as relative excess risk due to interaction (RERI), where an 
estimate of RERI that deviated from 0 was considered as evidence for an interaction. 
For the multiplicative scale, we estimated the interaction as the ratio of ORs, where a 
ratio that deviated from 1 was considered as evidence for an interaction.  
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4. Results 
4.1 Article 1 
In the first article, we found a significant association between infrequent of summer 
outdoor activity and increased MS risk in both Norway and Italy. The association was 
significant in all age periods in analyses combining the two countries, however the 
association was only significant during adolescence (13 to 18 years) in Norway and 
in early childhood (0 to 5 years) in Italy. Still, there were no significant differences 
between the two countries. In Norway, there was a significant association between 
frequent use of sunscreen and a higher MS risk after adjusting for frequency of 
outdoor activity during the same period.  Lastly, we found a significant higher risk of 
MS among those with red and blonde hair compared to those with black hair, which 
remained similar after adjusting for sunscreen use and frequency of outdoor activity. 
The results suggest that sun exposure, and most likely vitamin D, is important for MS 
risk. 
4.2 Article 2 
In the second article, we found that smoking, IM, indicators of vitamin D (frequency 
of outdoor activity, cod liver and fatty fish intake) and body size could not explain the 
association between level of education and MS risk in Norway. Higher level of 
education was associated with a marked lower MS risk, and this association remained 
similar when cases with early onset of disease were excluded.  Of all the risk factors 
most consistently associated with MS, only smoking confounded the association 
between education and MS risk. The findings suggest that currently unknown risk 
factors associated with level of education in Norway may be important for MS risk.  
4.3 Article 3 
In the third article, we found a significant negative multiplicative interaction between 
IM and smoking in the risk of MS. Among those who reported IM, we observed no 
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increased disease risk associated with smoking. Similarly, the effect estimates for the 
association between IM and MS risk were considerably lower among ever-smokers 
compared to never-smokers. The interaction was present in all three countries, 
although it did not reach statistical significance in Sweden. Furthermore, the direction 
of the estimated interaction on the additive scale was consistent with the interaction 
on the multiplicative scale, although the estimate did not reach statistical significance. 
The results indicate competing antagonism, where the two exposures compete to 
affect MS risk, and may thus operate on shared pathways  
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5. Discussion 
5.1 The contribution of the findings 
The findings in this thesis add to the evidence that childhood and especially 
adolescence are sensitive periods for exposure to environmental factors that 
contribute to MS risk later in life. While different studies have found associations 
between outdoor activity and sun exposure during prenatal period,166 childhood69, 167 
and adolescence,70 no prior study, to our knowledge, has examined age-periods from 
birth to age 30 in one single study, and thus comparing all these periods in the same 
population using the same methodology. We observed the most pronounced 
association during childhood and adolescence, which is consistent with the time 
period when other risk factors for MS appears to be important.48 It is also consistent 
with the early migration study of Kurtzke et al. where the MS rate among individuals 
migration before age 15 was similar as the rate in native-born population in their new 
country, while the rate among those migrating after this age was similar to the rate in 
their home country.50 It is also interesting to note that intake of cod liver oil, a source 
of vitamin D, among Norwegian participants in EnvIMS was inversely associated 
with MS risk only in the winter, when sun exposure is insufficient for vitamin D 
production, and only significant during adolescence, which is the same as observed 
for summer outdoor activity in Norway.83 
In this thesis, we have also contributed with new findings that previously have not 
been reported. We found an association between sunscreen and MS risk in Norway, 
which add to the evidence linking sun exposure and vitamin D to MS risk. Sunscreen 
blocks vitamin D production when applied according to World Health Organization 
(WHO) recommendations.168 However, it is unclear whether these findings can be 
translated into real-life situations, as a randomized controlled trial where participants 
applied the sunscreen themselves found no significant association between sunscreen 
use and circulating 25-hydroxyvitamin D levels.169 Similar findings were made in a 
different study, and the authors speculated whether this was due to sunscreen not 
being applied adequately or on all sun exposure areas.170 We only found the 
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association in early childhood in Norway, when sunscreen is likely to be more 
thoroughly applied by parents compared to later in life. It has previously been 
estimated that when as little as 9% of the body, corresponding to head and neck, is 
free of sunscreen, vitamin D production can occur.171 This could explain why we did 
not find an association in Italy, as the question in the Italian EnvIMS-Q was not 
limited to sunscreen only, but also protective clothing.  
Further, while several previous studies have examined the interaction between 
smoking and different measures of EBV, our study is the first to report a significant 
interaction. This could be due to the size of our study, as interaction analyses are 
particularly dependent on sample size,172 and that we are focusing on IM and not 
serum antibodies against EBV, such as EBNA-1. As EBNA-1 levels do not seem to 
predict a positive history of IM,173 and that the two measures of EBV infection are 
independently associated with MS risk,174 they are likely to reflect different aspects of 
an EBV infection. Thus, studies on the interaction between EBNA-1 levels and 
smoking do not necessarily compare with ours. Overall, our findings suggest that IM 
and smoking operate on shared biological pathways in how they affect MS risk. 
Lastly, while one previous study examined the association between different 
measures of SES and MS risk while controlling for most of the established risk 
factors for MS, they could not account for vitamin D,147 which is likely to have causal 
role in MS etiology.84, 85 We were able to adjust for different markers of vitamin D 
levels, including outdoor activity, dietary intake of vitamin D supplements and fatty 
fish intake, which all were associated with MS risk in EnvIMS.83, 175 This adds to the 
evidence that lower SES is associated with higher MS risk independently of known 
risk factors, which suggests that currently unknown environmental factors associated 
with SES are important for disease risk.  
One advantage of EnvIMS is that we are able to compare associations in different 
populations using the same methodology. While the interaction between smoking and 
IM was consistent in the three countries included in the third article, we observed 
some differences in the association between outdoor activity and MS risk in Norway 
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and Italy. This could be due to different effect of the exposures in the two countries, 
as smoking and IM are likely to have similar effects in Norway and Italy, while the 
same amount of outdoor activity in the two countries contributes to different amount 
of sun exposure and vitamin D production due to variation in UV radiation.75 It is 
likely that sun exposure during summer contributes more to overall vitamin D levels 
over a year in Norway compared to Italy, as vitamin D production is possible for a 
longer period during the year in Italy.75 This could explain why the association was 
more pronounced in Norway compared to Italy, especially during adolescence where 
it was not significant in Italy. Further, the differences could also be due to variation in 
sun seeking behavior in the two countries, as very few participants reported 
infrequent amount of outdoor activity in early childhood in Norway, but close to 10% 
reported this in Italy. Sunscreen behavior could be more important during this period 
in Norway, as very few spend time inside. Lastly, we observed that frequency of 
outdoor activity was inversely associated with MS risk during the last age period in 
Italy (26-30), while the association was least pronounced, and not significant, in 
Norway in this period. Disease processes in MS are likely to start several years before 
the first symptom of the disease and heat sensitivity is a common symptom among 
patients.176, 177 Therefore, these findings could to some extent reflect reverse causality 
as this age period is close to the reported mean age of onset among the Italian 
participants. Heat sensitivity may also be a larger problem in Italy than in Norway 
due to higher overall temperatures.177 Still, it is important to note that we did not find 
any significant differences in the two countries when testing for heterogeneity in the 
effect estimates in the two countries, and the observed differences could thus be due 
to random error. 
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5.2 Methodological considerations and limitations 
5.2.1 Direct acyclic graphs (DAGs) 
DAG is a specific type of graph developed by Judea Pearl, and is useful to classify 
assumptions and problems in study designs and models.178 I will use DAGs to 
illustrate methodological considerations and limitations in the articles included in this 
thesis, and will therefore briefly describe some of the theory behind these here.  
A detailed description of DAGs has been published by Pearl.179 In short, a graph 
consists of nodes representing variables and edges denoting the relationship between 
the variables. A graph is a DAG when it is both directed, which means that all edges 
denote a direction (i.e. they are arrows), and is acyclic, which means that the graph 
does not include any cycles implying that a variable cannot cause itself. Several 
variables connected by arrows form a path, and information in a DAG can flow 
between these variables depending on the direction of the relationship between them. 
Information can flow along a path if all arrows point in the same direction or if an 
intermediate variable is a common cause, as long as we do not condition on any of 
the variables involved in these paths. 
 
In Figure 8.1, we assume that all the effect of sun exposure (S) on MS (Y) is 
mediated by vitamin D (D), and thus the information flows from S to Y through D. In 
Figure 8.2 we assume that both sun exposure (S) and vitamin D (D) affects MS risk 
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(Y), and that sun exposure (S) is a common cause of both vitamin D (D) and MS (Y). 
Information will thus flow from D to Y and from D to Y through S. In this DAG, the 
association between D and Y will be a combination of the information on flowing on 
path D to Y and D to Y through S. 
An important concept in DAGs is directional-separation (d-separation), which is used 
to determine whether two variables are independent of each other.179 Two variables 
are d-separated, or independent, if conditioning (e.g. by stratifying or adjusting in a 
regression model) on a mediator or a common cause, blocks every path between the 
two variables. 
 
In Figure 9.1, we have conditioned on vitamin D (D), which is denoted by a square 
around the variable, and have therefore blocked all paths from sun exposure (S) to 
MS (Y). If this DAG is correct, we would not expect any association between sun 
exposure and MS if we condition on vitamin D, and the two variables are thus d-
separated conditional on vitamin D.  In Figure 9.2, we have conditioned on the 
common cause sun exposure (S). If this blocks all paths from vitamin D (D) to MS 
(Y), then vitamin D and MS are d-separated conditional on sun exposure, indicating 
that any initial association was due confounding by sun exposure. If there is still an 
association after conditioning on sun exposure, then vitamin D is associated with MS 
independent of sun exposure, as we have blocked the path from vitamin D to MS 
through sun exposure.  
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Lastly, two variables are d-separated if there is a common effect on the path between 
them, which is often referred to as a collider. In Figure 10.1, the path between genetic 
predisposition for MS (G) and vitamin D (D) is blocked by the common effect MS 
(Y), and we would not expect any association between them given that the DAG is 
correct. However, if we condition on a common effect, as illustrated in Figure 10.2, 
we open up the path between D and G. Thus, within MS patients there may be an 
association between G and D, as we have stratified (i.e. conditioned) on disease 
status. 
 
5.2.2 Selection bias 
Selection bias is a bias that occurs when we condition on a common effect.180 In a 
study, we condition on participation as we only observe those who chose to take part 
in the study (i.e. we stratify on participation). As exposure and disease can be 
associated with the likelihood of participating, we may induce an association between 
them by conditioning on the common effect and thus get biased results. This can be 
illustrated by the association examined in the second article in this thesis, the 







In this DAG, there is an arrow from MS (Y) to participation (P), as those affected by 
a disease often are more motivated to take part in a study,180 which was also the case 
in EnvIMS. There is also an arrow from level of education (E) to participation (P), as 
those with a higher level of education are more likely to be motivated to take part in 
research compared to those with lower level of education.181 By conditioning on the 
common effect participation (P), we open up the path between level of education (E) 
and MS (Y) through P, and can therefore induce an association between education 
and MS. Thus, the observed association in this article may be due to selection bias 
rather than representing an association that also would be present in the source 
population. 
While we cannot exclude that the results from the articles in this thesis are due to 
selection bias, it is unlikely that it can fully explain them. The results from the article 
on education and MS risk are consistent with two prospective registry-based studies 
in Norway,146, 182 which are unlikely to be affected by selection bias. This is because 
the participants were free of disease at study start, which makes it unlikely that there 
is an association between the outcome they eventually develop and the likelihood to 
take part in the study in the first place. The effect estimate in our study (OR 0.53, 
95% CI: 0.41-0.68) was similar to the one reported in the largest study on education 
and MS risk in Norway by Riise et al. (rate ratio [RR] 0.48, 95% CI 0.53-0.88),146 
and our results are consistent with the findings of Bjørnevik et al. in a registry-based 
sibling study.182 Further, findings of the environmental risk factors most consistently 
associated with MS risk have been reproduced in EnvIMS, which makes it unlikely 
that our findings can be fully explained by selection bias. 
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5.2.3 Recall bias 
Information in epidemiological studies is unlikely to be measured perfectly, and there 
is therefore measurement error or misclassification in our variables. This can be non-
differential or differential by disease status, i.e. whether the misclassification varies 
with disease status. Case-control studies are prone to differential misclassification by 
disease status, as exposure is retrospectively recalled after the development of the 
outcome, and patients may recall prior exposure differently than controls.183 This is 
referred to as recall bias, and can be illustrated by the first article in this thesis, the 
association between outdoor activity and MS risk (Figure 12). 
 
We were interested in the association between outdoor activity (O) and MS (Y). The 
frequency of outdoor activity reported in the study (O*) is affected by measurement 
error (MO), which again is affected by disease status MS (Y), as patients may recall 
prior exposure differently than the controls. Since there is an open path from O* to 
MO to Y, we are not able to isolate the association of O* through O to Y. The results 
from our study may thus be affected by recall bias.  
We cannot exclude that the results in this thesis are affected by recall bias, but 
similarly to selection bias, it is unlikely that it can fully explain them. First, it is 
unlikely that we would observe age-specific associations, like those observed for 
outdoor activity, as recall bias would have to selectively affect recall of exposure in 
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some age-periods and not in others. Further, it is unlikely that recall bias would vary 
across strata of another risk factor, and thus explain the findings of an interaction in 
the third article in this thesis. Lastly, the associations we found between vitamin D 
related factors, smoking, body size and MS risk are consistent with results from 
prospective studies, which are not affected by recall bias as information on exposure 
is collected before the participants develop the outcome.  
5.2.4 Confounding 
Confounding is a bias that occur when an exposure and an outcome share a common 
cause.180 One of the main problems with making causal interpretations using 
observational studies is that confounders that we do not have data on can affect the 
associations we observe. This means that the criteria of exchangeability, which means 
that the risk of the outcome in the unexposed group would have been the same as in 
the exposed group if we would have switched the exposure status,180 is unrealistic in 
observation studies.  
It is likely that our findings are affected by unmeasured confounding. Still, MR 
studies on vitamin D and obesity suggests a causal role of these factors in MS risk,84, 
85, 134 and these findings are consistent with the findings in EnvIMS, suggesting that 
unmeasured confounding cannot fully explain these specific associations in EnvIMS. 
Although consistent results with other observational studies do not exclude the 
possibility that unmeasured confounding can fully explain our findings, it makes it 
less likely. 
5.2.5 Additive and multiplicative interaction analysis 
If the effect of one exposure on an outcome depends on the presence of another 
exposure, then there is an interaction between the two exposures.165 Within the 
counterfactual framework, it is common to limit the term interaction to potential 
interventions, to differentiate the term from effect modification.180 Interactions are 
further complicated by the fact that they are scale-dependent, which means that the 
presence of an interactions depends on the scale they are analyzed on.151 This makes 
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it possible to have an interaction on the additive scale, but not on the multiplicative 
scale, and also possible to have an interaction on the multiplicative scale, but not on 
the additive scale. Furthermore, when both exposures have an effect on the outcome, 
there will always be an interaction on at least one scale.151 The main argument for the 
use of an additive scale is that it is a better scale to assess the public health 
importance of interventions and interactions.151 On the other hand, it may be more 
natural to assess interactions on the multiplicative scale when using multiplicative 
statistical models, such as logistic regression, as the model is exponential and thus 
multiplicative. Furthermore, interactions on a multiplicative scale are often easier to 
estimate. As arguments can be made for both scales, it is best to report the 
interactions on both.165 In the third article included in this thesis, we found an 
interaction both on the additive and the multiplicative scale, which adds weight to the 
findings. 
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6. Further perspectives 
In this thesis, we have contributed with new knowledge on established risk factors, 
including how the association between outdoor activity, and thus likely vitamin D 
exposure, and MS risk vary with age. This adds to the evidence that childhood and 
especially adolescence are sensitive periods for exposure to environmental factors 
that contribute to MS risk later in life. This would be important to consider in a study 
aiming to assess the effect of primary prevention of MS through modification of 
known risk factors.  
We have also contributed with novel findings that previously have not been reported, 
including the findings on sunscreen use, SES and the negative interaction between IM 
and smoking. Our findings suggest that currently unknown environmental factors 
contribute to disease risk, and that these may be associated with lower SES. This 
could be useful to consider in studies aiming to identify new risk factors for the 
disease. Further, if smoking and IM affects MS risk on shared biological pathways, as 
suggested by the third article, this would be important to consider in studies aiming to 
identify the mechanisms contributing to the pathogenesis of MS. As discussed above, 
it is unlikely that the new findings can be fully explained by selection and recall bias, 
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